Lioton (Heparin Sodium)

Heparin Sodium enhances the activity of antithrombin III, which blocks thrombin and factor Xa in the coagulation cascade. This inhibition reduces fibrin formation, thereby limiting clot development at the site where the product is applied.

The specific dose and frequency of Lioton are determined by the prescribing healthcare professional based on the patient’s condition, the size of the area to be treated, and clinical judgment. Patients should follow the prescriber’s instructions exactly.

Safety of topical Heparin Sodium during pregnancy or lactation has not been definitively established. Healthcare providers should weigh potential benefits against any possible risks before prescribing Lioton to pregnant or nursing individuals.

To order Lioton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with systemic anticoagulants, Lioton provides localized action with minimal systemic exposure, making it suitable for superficial conditions. Unlike oral agents, it does not require systemic monitoring, but it is not a substitute for systemic therapy when deep‑vein thrombosis or major clotting disorders are present.

Lioton should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

Lioton is applied topically to clean, dry skin. A thin layer is spread over the affected area as directed by the prescriber, usually once or twice daily, and gently massaged until absorbed. Hands should be washed before and after application.

The most serious risks include systemic anticoagulation leading to unexpected bleeding, Heparin‑induced thrombocytopenia (HIT), severe allergic reactions such as anaphylaxis, and local skin necrosis. Patients should seek immediate medical attention if they notice unusual bruising, bleeding, or skin changes.

Lioton should not be used by individuals with known hypersensitivity to Heparin Sodium or any excipients in the formulation, by patients with active skin infections at the application site, or by those with a history of heparin‑induced thrombocytopenia unless specifically advised by a healthcare professional.